Prospa announces pricing of its third public ABS issuance backed by SME loans

ASX-listed Prospa have announced the pricing of its third public asset-backed securities (ABS) offering of AUD $200 million issued to wholesale investors, supported by a pool of Australian small business loans and line of credit facilities.

The PROSPArous Trust 2024-1 is the third of its kind in Australia, following Prospa’s two previous transactions.

Moody’s is expected to lift their credit rating cap from Aa3 to Aa2, demonstrating Prospa’s continuing role as an innovator in Australia’s securitisation market.

The transaction was fully subscribed for Class A-F Notes, with demand from large real money local investors. It takes place as the Australian SME market continues to demonstrate resilience in the current environment.

Ross Aucutt, Chief Financial Officer of Prospa, said, “We’re happy to have priced our third ABS in four years; establishing us as a regular and reliable issuer. We are grateful for the strong engagement from investors, and this will allow us to support small business owners with working capital and investment headroom. We were extremely pleased at the strong support from new and existing investors in the transaction.”

The transaction is expected to settle on 11 April 2024, subject to the satisfaction of customary conditions precedent.

Source link


gaitQ and machineMD secure million dollar research grant to monitor Parkinson’s development in UK and Switzerland

Oxford-based medical technology start-up gaitQ and Swiss medical device company machineMD have announced the joint award of a million dollar research grant from Innovate UK and Innosuisse to enable the collection and analysis of critical movement data from people with Parkinson’s (PwP). The grant will fund an 18-month research project that will record movement data […]

Read More

Take-Two plans to lay off 5 percent of its employees by the end of 2024

Take-Two Interactive plans to lay off 5 percent of its workforce, or about 600 employees, by the end of the year, as reported in an SEC filing Tuesday. The studio is also canceling several in-development projects. These moves are expected to cost $160 million to $200 million to implement, and should result in $165 million […]

Read More

10 tips to avoid planting AI timebombs in your organization

At the recent HIMSS Global Health Conference & Exhibition in Orlando, I delivered a talk focused on protecting against some of the pitfalls of artificial intelligence in healthcare. The objective was to encourage healthcare professionals to think deeply about the realities of AI transformation, while providing them with real-world examples of how to proceed safely […]

Read More